Preface

Cervical cancer (CxCA) is one of very few types of cancer that have experienced remarkable progress in scientific, clinical, and socioeconomic areas. The discovery of the first high-risk human papillomavirus (HPV) types by Zur Hausen’s group in the early 1980s opened the doors to research on the viral origin of cervical cancer. Some 30 years later, it is generally accepted that high-risk HPV types represent the major etiologic agents of CxCA. Cytological screening and HPV genotyping in women have become routine in many countries. Because of the sexually transmittable nature of HPVs, men are being enrolled in large-scale screening programs as well. In addition, two effective HPV vaccines have been developed and implemented by many countries, and novel vaccination modalities or immunotherapies are in clinical trials. In brief, our knowledge base and know-how with regard to all aspects of CxCA have grown considerably over the last three decades.

In order to adequately represent the most relevant procedures and technologies that continue to advance the field of HPV-mediated carcinogenesis of the cervix and other anatomical regions of squamocolumnar transition (anorectum, penis, and oropharynx), we have compiled a series of protocols into two parts with the first part covering HPV types, pathogenesis of CxCA, prevention, and novel potential drug targets, and the second part exploring pathology, genomics, modeling of CxCA, and experimental therapeutic strategies. Part I is subdivided into four major sections containing protocols for the detection and genotyping of high-risk HPV types; for studying the molecular pathogenesis of CxCA; for analyzing the impact of current immune responses to HPV infections; and for the identification of novel drug targets. In the second half, readers will find essential protocols for the histopathological detection, typing, and staging of CxCA; for performing genomic analysis of CxCA; and for modeling human CxCA in the culture dish or in mice and testing novel therapeutic avenues.

Each protocol in the Methods in Molecular Biology series is, on average, fourteen pages long and organized into six sections, i.e., a brief “Summary,” an “Introduction,” “Materials” and “Methods” sections, a “Notes” section, and “References.” The “Notes” section is particularly useful as it highlights potential problem areas and ways to troubleshoot them, some variations in procedures, as well as assay sensitivity and timescale.

With this collection of close to 30 protocols, which faithfully cover the spectrum of techniques and strategies currently in use across the globe, we hope to provide a valuable resource to both bench scientists and clinicians who step into the realm of high-risk HPVs and CxCA for the first time or who wish to learn novel approaches or expand their toolbox for the study of CxCA.

We wish to extend our warmest thanks to Professor John M. Walker (Series Editor), who has provided amazing guidance and support during the realization of this project, and to all contributors of protocols for their hard work and patience.

Vallejo, CA, USA

Daniel Keppler
Athena W. Lin
Contents

Preface ................................................................. v
Contributors ......................................................... xi

PART I  APPROACHES TO THE DETECTION AND ANALYSIS OF HPV TYPES

1 Evolution and Classification of Oncogenic Human Papillomavirus Types and Variants Associated with Cervical Cancer ......................................................... 3
   Zigui Chen, Luciana Bueno de Freitas, and Robert D. Burk

2 A Real-Time PCR Approach Based on SPF10 Primers and the INNO-LiPA HPV Genotyping Extra Assay for the Detection and Typing of Human Papillomavirus ......................................................... 27
   M. Isabel Micalessi, Gaëlle A. Boulet, and Johannes Bogers

PART II  MOLECULAR PATHOGENESIS OF CXCA

3 Replication of Human Papillomavirus in Culture .............................................. 39
   Eric J. Ryndock, Jennifer Biryukov, and Craig Meyers

4 HPV Binding Assay to Laminin-332/Integrin α6β4 on Human Keratinocytes .................. 53
   Sarah A. Brendle and Neil D. Christensen

5 Methods to Assess the Nucleocytoplasmic Shuttling of the HPV E1 Helicase and Its Effects on Cellular Proliferation and Induction of a DNA Damage Response ........................................... 67
   Michaël Lehoux, Amélie Fradet-Turcotte, and Jacques Archambault

6 Genetic Methods for Studying the Role of Viral Oncogenes in the HPV Life Cycle .................. 81
   Jason M. Bodily

7 Robust HPV-18 Production in Organotypic Cultures of Primary Human Keratinocytes .................. 93
   Hsu-Kun Wang, Thomas R. Broker, and Louise T. Chow

8 A High-Throughput Cellular Assay to Quantify the p53-Degradation Activity of E6 from Different Human Papillomavirus Types ................................................. 111
   David Gagnon and Jacques Archambault

9 Retroviral Expression of Human Cystatin Genes in HeLa Cells .......................... 121
   Crystal M. Diep, Gagandeep Kaur, Daniel Keppler, and Athena W. Lin

PART III  IMMUNE RESPONSES TO HPV INFECTIONS

10 Molecular Analysis of Human Papillomavirus Virus-Like Particle Activated Langerhans Cells In Vitro .......................... 135
    Andrew W. Woodham, Adam B. Raff, Diane M. Da Silva, and W. Martin Kast
PART IV IDENTIFICATION OF NOVEL POTENTIAL DRUG TARGETS

11 Selective Silencing of Gene Target Expression By siRNA Expression Plasmids in Human Cervical Cancer Cells ........................................... 153
Oscar Peralta-Zaragoza, Faustino De la O-Gómez, Jessica Deas, Gloria Fernández-Tilapa, Geny del Socorro Fierros-Zárate, Claudia Gómez-Cerón, Ana Burguete-García, Kirvis Torres-Poveda, Victor Hugo Bermúdez-Morales, Mauricio Rodríguez-Dorantes, Carlos Pérez-Plasencia, and Vicente Madrid-Marina

12 Silencing of E6/E7 Expression in Cervical Cancer Stem-Like Cells .......... 173
Wenyi Gu, Nigel McMillan, and Chengzhong Yu

13 Two-Step Procedure for Evaluating Experimentally Induced DNA Damage: Texas Red and Comet Assays ..................................................... 183
Gina J. Ferris, Lauren B. Shunkwiler, and Charles A. Kunos

14 Measurement of Deubiquitinating Enzyme Activity Via a Suicidal HA-Ub-VS Probe ................................................................. 193
Colleen Rivard and Martina Bazzaro

PART V APPROACHES TO DETECTING, TYING, AND STAGING OF CxCA

15 Immunocytochemical Analysis of the Cervical Pap Smear ....................... 203
Terry K. Morgan and Michelle Berlin

16 Diagnosis of HPV-Negative, Gastric-Type Adenocarcinoma of the Endocervix .............................................................. 213
Edyta C. Pirog

17 Targeting of the HPV-16 E7 Protein by RNA Aptamers .......................... 221
Julia Dolores Toscano-Garibay, María Luisa Benítez-Hess, and Luis Marat Alvarez-Salas

18 The Use of MYBL2 as a Novel Candidate Biomarker of Cervical Cancer .... 241
Cara M. Martin, Katharine Astbury, Louise Keboe, Jacqueline Barry O’Crowley, Sharon O’Toole, and John J. O’Leary

19 Fixation Methods for the Preservation of Morphology, RNAs, and Proteins in Paraffin-Embedded Human Cervical Cancer Cell Xenografts in Mice ........ 253
Yoko Matsuda and Toshiyuki Ichiwata

PART VI GENOMIC ANALYSES OF CxCA

20 Assessment of the HPV DNA Methylation Status in Cervical Lesions ........ 267
Mina Kalantari and Hans-Ulrich Bernard

21 MeDIP-on-Chip for Methylation Profiling ........................................... 281
Yaw-Wen Hsu, Rui-Lan Huang, and Hung-Cheng Lai

22 Use of DBD-FISH for the Study of Cervical Cancer Progression ............ 291
Elva I. Cortés-Gutiérrez, Jose Luis Fernández, Martha I. Dávila-Rodríguez, Carmen López-Fernández, and Jaime Gosálvez
PART VII  CELLULAR ASSAYS AND CELL CULTURE MODELS OF CxCA

23  A Quantitative and High-Throughput Assay of Human Papillomavirus DNA Replication ......................................................... 305
    David Gagnon, Amélie Fradet-Turcotte, and Jacques Archambault

24  Native Human Papillomavirus Production, Quantification, and Infectivity Analysis ......................................................... 317
    Jennifer Biryukov, Linda Cruz, Eric J. Ryndock, and Craig Meyers

25  Functional Analysis of HPV-Like Particle-Activated Langerhans Cells In Vitro ................................................................. 333
    Lisa Yan, Andrew W. Woodham, Diane M. Da Silva, and W. Martin Kast

26  Assessment of the Radiation Sensitivity of Cervical Cancer Cell Lines ................................................................. 351
    Mayil Vahanan Bose and Thangarajan Rajkumar

PART VIII  ANIMAL MODELS OF CxCA AND EXPERIMENTAL THERAPEUTIC STRATEGIES

27  Mouse Model of Cervicovaginal Papillomavirus Infection ................................................................. 365
    Nicolas Çuburu, Rebecca J. Cerio, Cynthia D. Thompson, and Patricia M. Day

28  Establishment of Orthotopic Primary Cervix Cancer Xenografts ................................................................. 381
    Naz Chaudary, Karolina Jaluba, Melania Pintilie, and Richard P. Hill

29  Generation of K14-E7/ΔN87βcat Double Transgenic Mice as a Model of Cervical Cancer ................................................................. 393
    Gülay Bulut and Aykut Üren

Index ................................................................................................................. 407
Contributors

LUIS MARAT ALVAREZ-SALAS • Laboratorio de Terapia Génica, Departamento de Genética y Biología Molecular, CINVESTAV, México, DF, Mexico

JACQUES ARCHAMBAULT • Laboratory of Molecular Virology, Institut de Recherches Cliniques de Montréal, Montreal, QC, Canada; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montreal, QC, Canada

KATHARINE ASTBURY • Department of Obstetrics and Gynaecology, Galway University Hospital, Galway, Ireland

MARTINA BAZZARO • Department of Obstetrics & Gynecology & Women’s Health, University of Minnesota Medical School, Minneapolis, MN, USA

MARÍA LUISA BENÍTEZ-HESS • Laboratorio de Terapia Génica, Departamento de Genética y Biología Molecular, CINVESTAV, México, DF, Mexico

MICHELLE BERLIN • Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, OR, USA

VICTOR HUGO BERMÚDEZ-MORALES • Direction of Chronic Infections and Cancer, Research Center in Infection Diseases, National Institute of Public Health, Cuernavaca, MOR, Mexico

HANS-ULRICH BERNARD • Department of Molecular Biology and Biochemistry, School of Biological Sciences, University of California Irvine, Irvine, CA, USA

JENNIFER BIRYUKOV • Department of Microbiology and Immunology, Pennsylvania State University College of Medicine, Hershey, PA, USA

JASON M. BODILY • Department of Microbiology and Immunology, Health Sciences Center, Louisiana State University, Shreveport, LA, USA

JOHANNES BOGERS • Applied Molecular Biology Research (AMBIOR) Group, Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium

MAYIL VAHANAN BOSE • Department of Molecular Oncology, Cancer Institute (WIA), Chennai, India

GAËLLE A. BOULET • Applied Molecular Biology Research (AMBIOR) Group, Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium

SARAH A. BRENDLE • Jake Gittlen Cancer Research Foundation, Pennsylvania State University College of Medicine, Hershey, PA, USA

THOMAS R. BROKER • Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, USA

GÜLAY BULUT • Department of Genetics and Bioinformatics, Faculty of Arts and Sciences, Babes-Eötvös University, Budapest, Hungary

ANA BURGUETE-GARCÍA • Direction of Chronic Infections and Cancer, Research Center in Infection Diseases, National Institute of Public Health, Cuernavaca, MOR, Mexico

ROBERT D. BURK • Albert Einstein College of Medicine, Bronx, NY, USA

REBECCA J. CERIO • Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

NAZ CHAUDHARY • Ontario Cancer Institute & Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre & University Health Network, Toronto, ON, Canada
Contributors

ZIGUI CHEN • Albert Einstein College of Medicine, Bronx, NY, USA
LOUISE T. CHOW • Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, USA
NEIL D. CHRISTENSEN • Jake Gittlen Cancer Research Foundation and Department of Pathology, Pennsylvania State University College of Medicine, Hershey, PA, USA
ELVA I. CORTÉS-GUTIERREZ • Department of Genetics, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social (IMSS), Monterrey, Nueva Leon, Mexico
LINDA CRUZ • Department of Microbiology and Immunology, College of Medicine, The Pennsylvania State University, Hershey, PA, USA
NICOLAS CUBURU • Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
MARThA I. DÁVILA-RODRÍGUEZ • Department of Genetics, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social (IMSS), Monterrey, Nueva Leon, Mexico
PATRICIA M. DAY • Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
JESSICA DEAS • Direction of Chronic Infections and Cancer, Research Center in Infection Diseases, National Institute of Public Health, Cuernavaca, MOR, Mexico
CRYSTAL M. DIEP • College of Pharmacy, Touro University California, Vallejo, CA, USA
JOSE LUIS FERNÁNDEZ • Genetics Unit, INIBIC, Complejo Hospitalario Universitario A Coruña, La Coruña, Spain; Laboratorio de Genética Molecular y Radiobiología, Centro Oncológico de Galicia, La Coruña, Spain
GLORIA FERNÁNDEZ-TILAPA • Clinical Research Laboratory, Academic Unit of Biological Chemical Sciences, Guerrero Autonomous University, Chilpancingo, Guerrero, Mexico
GINA J. FERRIS • Department of Radiation Oncology, Case Western Reserve University, Cleveland, OH, USA
GENY DEL SOCORRO FIERROS-ZÁRATE • Direction of Chronic Infections and Cancer, Research Center in Infection Diseases, National Institute of Public Health, Cuernavaca, MOR, Mexico
AMÉLIE FRADET-TURCOTTE • Laboratory of Molecular Virology, Institut de Recherches Cliniques de Montréal, Montreal, QC, Canada; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montreal, QC, Canada
LUCIANA BUENO DE FREITAS • Albert Einstein College of Medicine, Bronx, NY, USA
DAVID GAGNON • Laboratory of Molecular Virology, Institut de Recherches Cliniques de Montréal, Montreal, QC, Canada; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montreal, QC, Canada
CLAUDIA GÓMEZ-CERÓN • Direction of Chronic Infections and Cancer, Research Center in Infection Diseases, National Institute of Public Health, Cuernavaca, MOR, Mexico
JAIME GOSÁLVEZ • Unit of Genetics, Department of Biology, Universidad Autónoma de Madrid, Madrid, Spain
WENYI GU • Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia
RICHARD P. HILL • Ontario Cancer Institute & Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Departments of Medical Biophysics and Radiation Oncology, University of Toronto, Toronto, ON, Canada
YAW-WEN HSU • Department of Obstetrics and Gynecology, Tri-Service General Hospital and Graduate Institute of Life Sciences, National Defense Medical Center, Taipei City, Taiwan, ROC
RUI-LAN HUANG • Department of Obstetrics and Gynecology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, ROC

TOSHIYUKI ISHIWATA • Departments of Pathology and Integrative Oncological Pathology, Nippon Medical School, Bunkyo-ku, Tokyo, Japan

KAROLINA JALUBA • Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre & University Health Network, Toronto, ON, Canada

MINA KALANTARI • Department of Molecular Biology and Biochemistry, School of Biological Sciences, University of California Irvine, Irvine, CA, USA

W. MARTIN KAST • Departments of Molecular Microbiology & Immunology, Obstetrics & Gynecology and Urology, Keck School of Medicine & Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA

GAGANDEEP KAUR • College of Pharmacy, Touro University California, Vallejo, CA, USA

LOUISE KEOHE • Department of Pathology, The Coombe Women and Infants University Hospital, Dublin, Ireland

DANIEL KEPPLER • Department of Biological & Pharmaceutical Sciences, College of Pharmacy, Touro University California, Vallejo, CA, USA

CHARLES A. KUNOS • Department of Radiation Oncology, Summa Health System, Akron, OH, USA

HUNG-CHENG LAI • Department of Obstetrics and Gynecology, Shuang Ho Hospital & School of Medicine, Taipei Medical University, New Taipei City, Taiwan, ROC; Department and Graduate Institute of Biochemistry, Graduate Institute of Life Sciences, National Defense Medical Center, New Taipei City, Taiwan, ROC

MICHAEL LEHOUX • Laboratory of Molecular Virology, Institut de Recherches Cliniques de Montréal, Montreal, QC, Canada

ATHENA W. LIN • Department of Basic Science, College of Osteopathic Medicine, Touro University California, Vallejo, CA, USA

CARMEN LÓPEZ-FERNÁNDEZ • Unit of Genetics, Department of Biology, Universidad Autónoma de Madrid, Madrid, Spain

VICENTE MADRID-MARINA • Direction of Chronic Infections and Cancer, Research Center in Infection Diseases, National Institute of Public Health, Cuernavaca, MOR, Mexico

CARA M. MARTIN • Department of Histopathology, Trinity College, University of Dublin, Dublin, Ireland; The Coombe Women and Infants University Hospital, Dublin, Ireland

YOKO MATSUDA • Departments of Pathology and Integrative Oncological Pathology, Nippon Medical School, Bunkyo-ku, Tokyo, Japan

NIGEL McMILLAN • Cancer Research Centre & Griffith Health Institute & School of Medical Science, Griffith University, Southport, QLD, Australia

CRAIG MEYERS • Department of Microbiology and Immunology, College of Medicine, The Pennsylvania State University, Hershey, PA, USA

M. ISABEL MICALESSI • Applied Molecular Biology Research (AMBIOR) Group, Laboratory of Cell Biology and Histology, Vaccine & Infectious Diseases Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium

TERRY K. MORGAN • Departments of Pathology, Oregon Health & Science University, Portland, OR, USA; Departments Obstetrics & Gynecology, Oregon Health & Science University, Portland, OR, USA

JACQUELINE BARRY O’CROWLEY • Department of Pathology, The Coombe Women and Infants University Hospital, Dublin, Ireland

JOHN J. O’LEYAR • Department of Histopathology, Trinity College, University of Dublin, The Coombe Women and Infants University Hospital, Dublin, Ireland
Contributors

SHARON O'TOOLE • Department of Obstetrics and Gynaecology, Trinity College, University of Dublin, Trinity Centre for Health Sciences, St. James's Hospital, Dublin, Ireland

FAUSTINO DE LA O-GÓMEZ • Direction of Chronic Infections and Cancer, Research Center in Infection Diseases, National Institute of Public Health, Cuernavaca, MOR, Mexico

OSCAR PERALTA-ZARAGOZA • Direction of Chronic Infections and Cancer, Research Center in Infection Diseases, National Institute of Public Health, Cuernavaca, MOR, Mexico

CARLOS PÉREZ-PLASENCIA • Oncogenomics Laboratory, National Cancer Institute, Mexico, DF, Mexico; Biomedicine Unit, FES-Iztacala UNAM, Tlahuapanla de Baz, Mexico

MELANIA PINTILIE • Biostatistics Department, Ontario Cancer Institute, Princess Margaret Cancer Centre & University Health Network, Toronto, ON, Canada

EDYTA C. PIROG • Clinical Pathology and Laboratory Medicine, Department of Pathology, Weill Medical College of Cornell University, New York, NY, USA; New York-Presbyterian Hospital, New York, NY, USA

ADAM B. RAFF • Departments of Molecular Microbiology & Immunology, Obstetrics & Gynecology and Urology, Keck School of Medicine & Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA

THANGARAJAN RAJKUMAR • Department of Molecular Oncology, Cancer Institute (WIA), Chennai, India

COLEEN RIVARD • Department of Obstetrics, University of Minnesota Medical School, Minneapolis, MN, USA

MAURICIO RODRÍGUEZ-DORANTES • National Institute of Genomic Medicine, Mexico, DF, Mexico

ERIC J. RINDDOCK • Department of Microbiology and Immunology, College of Medicine, Pennsylvania State University, Hershey, PA, USA

LAUREN B. SHUNKWILER • Department of Radiation Oncology, Case Western Reserve University, Cleveland, OH, USA

DIANE M. DA SILVA • Department of Obstetrics & Gynecology, Keck School of Medicine & Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA

CYNTHIA D. THOMPSON • Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

KIRVIS TORRES-POVEDA • Direction of Chronic Infections and Cancer, Research Center in Infection Diseases, National Institute of Public Health, Cuernavaca, MOR, Mexico

JULIA DOLORES TOSCANO-GARIBAY • Laboratorio de Medicina Regenerativa, Dirección de Investigación, Hospital Juárez de México, México, DF, Mexico

AYKUT ÜREN • Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA

HSU-KUN WANG • Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, USA

ANDREW W. WOODHAM • Department of Molecular Microbiology & Immunology, Keck School of Medicine & Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA

LISA YAN • Department of Molecular Microbiology and Immunology, Keck School of Medicine & Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA

CHENZHONG YU • Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia